Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C8H11NO4S2 |
| Molecular Weight | 249.307 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CSCC(=O)NC1CCSC1=O
InChI
InChIKey=QGFORSXNKQLDNO-UHFFFAOYSA-N
InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)
| Molecular Formula | C8H11NO4S2 |
| Molecular Weight | 249.307 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Erdosteine is an antioxidant compound developed by Edmond Pharma and approved in Europe for the treatment of chronic bronchitis and COPD. Erdosteine has two thiol groups and is believed to act as a free radicals scavenger (through the formation of the active metabolite I, N-thiodiglycolylhomocysteine). Also the drug effect may be due to the inhibition of the activity of elastase enzyme and its interaction with mucosa. The drug got Orphan Drug designation by FDA for the treatment of bronchiectasis.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. | 2007 Dec |
|
| Antioxidant systems and oxidative stress in the testes. | 2008 Oct-Dec |
|
| [Effects of erdosteine on inflammation and fibrosis in rats with pulmonary fibrosis induced by bleomycin]. | 2009 |
|
| Erdosteine and ebselen as useful agents in intestinal ischemia/reperfusion injury. | 2009 Aug |
|
| Erdosteine: its relevance in COPD treatment. | 2009 Mar |
|
| The protective effect of erdosteine on vancomycin-induced pancreatic damage in rats. | 2009 Nov |
|
| Raft of results energizes researchers. | 2009 Sep-Oct |
|
| Free radical scavenging activity of erdosteine metabolite I investigated by electron paramagnetic resonance spectroscopy. | 2010 |
|
| Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. | 2010 Apr |
|
| Effectiveness of erdosteine, a second generation mucolytic agent, in children with acute rhinosinusitis: a randomized, placebo controlled, double-blinded clinical study. | 2010 Apr |
|
| The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. | 2010 Apr |
|
| Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice. | 2010 Aug |
|
| Effects of sulphurous water on human neutrophil elastase release. | 2010 Dec |
|
| Association between lung function and exacerbation frequency in patients with COPD. | 2010 Dec 9 |
|
| Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. | 2010 Feb 8 |
|
| Erdosteine in renal ischemia-reperfusion injury: an experimental study in pigs. | 2010 Jan |
|
| Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. | 2010 Jan 6 |
|
| Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide. | 2010 Jul-Sep |
|
| Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study. | 2010 Jun |
|
| Combination antioxidant effect of α-tocoferol and erdosteine in ischemia-reperfusion injury in rat model. | 2010 Sep |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Mar 06 12:14:51 UTC 2018
by
admin
on
Tue Mar 06 12:14:51 UTC 2018
|
| Record UNII |
76J0853EKA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
R05CB15
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
||
|
WHO-VATC |
QR05CB15
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C61750
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY | |||
|
C048498
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY | |||
|
SUB06595MIG
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY | |||
|
CHEMBL1697744
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY | |||
|
24305
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY | RxNorm | ||
|
84611-23-4
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY | |||
|
65632
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY | SWITZERF | ||
|
M4974
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY | Merck Index | ||
|
84611-23-4
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY | |||
|
ERDOSTEINE
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY | |||
|
6032
Created by
admin on Tue Mar 06 12:14:51 UTC 2018 , Edited by admin on Tue Mar 06 12:14:51 UTC 2018
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
